In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.
News|Podcasts|December 8, 2025
ACT Brief: AI-Driven Repurposing Advances, GCP Adoption Challenges, and New CAR-T Milestone
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we look at how AI and in-silico methods are reshaping drug repurposing, why staggered ICH GCP rollouts are creating new operational pressure points, and the FDA’s latest CAR-T approval expanding treatment options in B-cell malignancies.
This is the Applied Clinical Trials Brief—your fast track to the latest developments shaping clinical operations and drug development.
- A new ACT
feature article highlights how AI-enabled repurposing, EHR-based real-world evidence, and synthetic patient modeling are accelerating the reuse of existing therapies, with major pharma now integrating computational approaches directly into discovery and development. These tools are shortening timelines, supporting regulatory submissions, and enabling broader therapeutic expansion as agencies grow more receptive to in-silico evidence. - In the final
segment of our conversation with Citeline’s Heidi Chen, she explains that sponsors are navigating a moving target as new ICH GCP guidelines take effect on different schedules worldwide. While the updates increase responsibilities for both sponsors and CROs, Chen expects innovation to remain strong as organizations work to integrate the requirements without slowing the pace of development, especially in fast-moving areas like CAR-T and GLP-1s. - And FDA has
approved Bristol Myers Squibb’s Breyanzi for adults with relapsed or refractory marginal zone lymphoma, making it the first and only CAR-T therapy authorized for five different cancer types. The decision strengthens Breyanzi’s position across B-cell malignancies and adds a new option for patients who have cycled through multiple prior therapies.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
Trending on Applied Clinical Trials Online
1
The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent
2
Comparing OpenAI and Mistral on Clinical Trial Matching
3
What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites
4
ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment
5